Select Publications

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.

Dickler MN et al. Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/ cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety. Proc ASCO 2007;Abstract 567.

Gnant M et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc ASCO 2008;Abstract LBA4.

Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 3.

Miles D et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc ASCO 2008;Abstract LBA1011.

Miller KD et al. Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). San Antonio Breast Cancer Symposium 2007a;Abstract 3063.

Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for msetastatic breast cancer. N Engl J Med 2007b;357(26):2666-76. Abstract

Muss HB et al. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. Proc ASCO 2008;Abstract 507.

Pegram M et al. Phase II combined biological therapy targeting the HER2 protooncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 301.

 

 

 

 

 

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Paul E Goss, MD, PhD
- Select publications

Martine J Piccart-Gebhart, MD, PhD
- Select publications

TUMOR PANEL CASE DISCUSSION
- Select publications

INTERVIEWS (continued)

Erica L Mayer, MD, MPH
- Select publications

Maria Theodoulou, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office